177 related articles for article (PubMed ID: 34290912)
1. A Case of De Novo Psoriasis Secondary to Nivolumab in a Patient With Metastatic Renal Cell Carcinoma.
Mullangi S; Ponnam S; Lekkala MR; Koya S
Cureus; 2021 Jun; 13(6):e15703. PubMed ID: 34290912
[TBL] [Abstract][Full Text] [Related]
2. Severe de-novo palmoplantar and nail psoriasis complicating Nivolumab treatment for metastatic melanoma.
Di Altobrando A; Bruni F; Alessandrini A; Starace M; Misciali C; Piraccini BM
Dermatol Ther; 2020 May; 33(3):e13363. PubMed ID: 32239596
[TBL] [Abstract][Full Text] [Related]
3. [Initially undetected de novo psoriasis triggered by nivolumab for metastatic base of the tongue carcinoma].
Troyanova-Slavkova S; Eickenscheidt L; Dumann K; Kowalzick L
Hautarzt; 2018 Aug; 69(8):674-680. PubMed ID: 29330579
[TBL] [Abstract][Full Text] [Related]
4. Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors.
Cutroneo P; Ingrasciotta Y; Isgrò V; Rullo EV; Berretta M; Fiorica F; Trifirò G; Guarneri C
Dermatol Ther; 2021 Mar; 34(2):e14830. PubMed ID: 33527643
[TBL] [Abstract][Full Text] [Related]
5. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
6. Cutaneous adverse effects of the immune checkpoint inhibitors.
Collins LK; Chapman MS; Carter JB; Samie FH
Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
[TBL] [Abstract][Full Text] [Related]
7. Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer.
C Guven D; Kilickap S; Guner G; Taban H; Dizdar O
J Oncol Pharm Pract; 2020 Jan; 26(1):256-258. PubMed ID: 31566114
[TBL] [Abstract][Full Text] [Related]
8. Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies.
Sibaud V; Meyer N; Lamant L; Vigarios E; Mazieres J; Delord JP
Curr Opin Oncol; 2016 Jul; 28(4):254-63. PubMed ID: 27136138
[TBL] [Abstract][Full Text] [Related]
9. Rare Adverse Events Related to Nivolumab, an Immune Checkpoint Inhibitor: A Case Series.
Ganta N; Alnabwani D; Keating S; Patel V; Bommu VJL; Dawoud R; Cheriyath P
Cureus; 2022 Feb; 14(2):e22070. PubMed ID: 35295363
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
Plachouri KM; Vryzaki E; Georgiou S
Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab-induced plaque morphea in a malign melanoma patient.
Acar A; Oraloglu G; Yaman B; Karaarslan I
J Cosmet Dermatol; 2021 Aug; 20(8):2645-2647. PubMed ID: 33355973
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo-like lesions in a patient treated with nivolumab for renal cell carcinoma.
Lolli C; Medri M; Ricci M; Schepisi G; Filograna A; De Giorgi U; Stanganelli I
Medicine (Baltimore); 2018 Dec; 97(52):e13810. PubMed ID: 30593172
[TBL] [Abstract][Full Text] [Related]
13. Immune checkpoint inhibitor-related dermatologic adverse events.
Geisler AN; Phillips GS; Barrios DM; Wu J; Leung DYM; Moy AP; Kern JA; Lacouture ME
J Am Acad Dermatol; 2020 Nov; 83(5):1255-1268. PubMed ID: 32454097
[TBL] [Abstract][Full Text] [Related]
14. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
Okiyama N; Tanaka R
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
[TBL] [Abstract][Full Text] [Related]
15. A case report of psoriasis flare following immunotherapy: Report of an important entity and literature review.
Politi A; Angelos D; Mauri D; Zarkavelis G; Pentheroudakis G
SAGE Open Med Case Rep; 2020; 8():2050313X19897707. PubMed ID: 31976071
[TBL] [Abstract][Full Text] [Related]
16. Immune-related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors.
Zarbo A; Belum VR; Sibaud V; Oudard S; Postow MA; Hsieh JJ; Motzer RJ; Busam KJ; Lacouture ME
Br J Dermatol; 2017 Jun; 176(6):1649-1652. PubMed ID: 27943234
[TBL] [Abstract][Full Text] [Related]
17. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
18. [Dermatologic toxicities of immune checkpoint inhibitors].
Sibaud V; Boulinguez S; Pagès C; Riffaud L; Lamant L; Chira C; Boyrie S; Vigarios E; Tournier E; Meyer N
Ann Dermatol Venereol; 2018 May; 145(5):313-330. PubMed ID: 29678394
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo Adverse Event Observed in a Patient With Durable Complete Response After Nivolumab for Metastatic Renal Cell Carcinoma.
Billon E; Walz J; Brunelle S; Thomassin J; Salem N; Guerin M; Vicier C; Dermeche S; Albiges L; Tantot F; Nenan S; Pignot G; Gravis G
Front Oncol; 2019; 9():1033. PubMed ID: 31649889
[No Abstract] [Full Text] [Related]
20. Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review.
Kim KH; Sim WY; Lew BL
Ann Dermatol; 2021 Jun; 33(3):284-288. PubMed ID: 34079191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
